- A London based biotechnology company has received Clinical Trial Authorization acceptance from the UK Medicines and Healthcare products Regulatory Agency to conduct a first-in-human Phase I trial for Entervax™, a vaccine candidate against typhoid
- Entervax is an oral, bivalent vaccine based on the Vaxonella® platform
- Prokarium said in a press release published on November 26, 2019, it anticipates dosing of the 1st subject to begin in the first quarter of 2020